Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 22/5/2017
SIETES contiene 91791 citas

 
 
 1 a 17 de 17 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Gargiulo G, Windecker S, da Costa BR, Feres F, Hong M-K, Gilard M, Kim H-S, Colombo A, Bhatt DL, Kim B-K, Morice M-C, Park KW, Chieffo A, Palmerini T, Stone GW, Valgimigli M. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ 2016;355:i5483. [Ref.ID 100878]
2.Enlace a cita original Cita con resumen
Montalescot G, Sabatine MS. Oral dual antiplatelet therapy: what have we learnt from recent trials?. Eur Heart J 2015:6 de agosto. [Ref.ID 99343]
3. Cita con resumen
Navarese EP, Andreotti F, Schulze V, Kolodziejczak M, Buffon A, Brouwer M, Costa F, Kowalewski M, Parati G, Lip GYH, Kelm M, Valgimigli M. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ 2015;350:h1618. [Ref.ID 98975]
4. Cita con resumen
Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto A, Botelho RV, King III SB, Negoita M, Liu M, de Paula JET, Mangione JA, Meireles GX, Castello Jr HJ, Nicolela Jr EL, Perin MA, Devito FS, Labrunie A, Salvadori Jr D, Gusmao M, Staico R, Costa Jr JR, de Castro JP, Abizaid AS, Bhatt DL, for the OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 2013;310:2510-22. [Ref.ID 96672]
5.Tiene citas relacionadas
Kojda G. Role of nicorandil in ischaemic preconditioning. Lancet 2002;360:1888-9. [Ref.ID 64361]
6.Tiene citas relacionadas
PRODIGY authors. Role of nicorandil in ischaemic preconditioning. Lancet 2002;360:1888. [Ref.ID 64360]
7.Tiene citas relacionadas
PRODIGY authors. Role of nicorandil in ischaemic preconditioning. Lancet 2002;360:1887-8. [Ref.ID 64359]
8.Tiene citas relacionadas
Duerden MG. Role of nicorandil in ischaemic preconditioning. Lancet 2002;360:1887. [Ref.ID 64358]
9. Cita con resumen
Anónimo. Prodigy condemned for migraine advice. Scrip 2000;2543:3. [Ref.ID 51094]
10. Cita con resumen
Anónimo. UK Prodigy guidelines to be reviewed. Scrip 2000;2520:5. [Ref.ID 49812]
11.
Anónimo. UK Prodigy prompts ABPI concerns. Scrip 1998;2388:6. [Ref.ID 41515]
12.
Anónimo. UK Prodigy 2nd phase under evaluation. Scrip 1998;2331:3. [Ref.ID 38092]
13.
Purves I, Nestor G, Williams K. Testing of PRODIGY continues. BMJ 1998;316:776-7. [Ref.ID 37588]
14.
Anónimo. High cost could sink UK Prodigy system. Scrip 1997;2215:3. [Ref.ID 32278]
15. Cita con resumen
Anónimo. UK prodigy scheme "does influence prescribing". Scrip 1997;2227:7. [Ref.ID 32087]
Seleccionar todas
 
 1 a 17 de 17